Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252601 | 0.83 | HCAR3 (0.66) | POLBHCAR3MAPTSMN1; SMN2NPC1 | |
| SCHEMBL9654359 | 0.82 | MAPT (0.59) | POLBHCAR3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL9218700 | 0.82 | KMT2A (0.51) | HCAR3GAAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL9220760 | 0.82 | HCAR3 (0.50) | POLBHCAR3MAPTSMN1; SMN2NPC1 | |
| SCHEMBL8521877 | 0.78 | RECQL (0.58) | HCAR3GAAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL6572192 | 0.77 | HCAR3 (0.49) | POLBHCAR3GAAMAPTSMN1; SMN2 | |
| SCHEMBL3143350 | 0.77 | POLB (0.61) | POLBGAAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL3220892 | 0.76 | HCAR3 (0.64) | HCAR3MAPTRAB9AMEN1KMT2A | |
| SCHEMBL4857452 | 0.75 | MAPT (0.61) | POLBMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL13012425 | 0.74 | POLB (0.43) | POLBMAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019046465-A2 | THERAPEUTIC INDOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046465-A2 | THERAPEUTIC INDOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | POLB 2618/4885HCAR3 902/4885GAA 3188/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | POLB 2324/4885HCAR3 888/4885GAA 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.